within Pharmacolibrary.Drugs.ATC.C;

model C01DA55
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.75,
    adminDuration  = 600,
    adminMass      = 0.08,
    adminCount     = 1,
    Vd             = 0.0033,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Pentaerithrityl tetranitrate (PETN) is an organic nitrate vasodilator used to prevent angina pectoris (chest pain) and is classified as a nitrate antianginal. PETN is sometimes available in combination preparations with other cardiovascular drugs. While PETN has historical and regional clinical use (primarily in Europe), it is not widely approved or commonly used in all countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated based on published PETN monotherapy data in healthy adults, as no direct published pharmacokinetics for combinations (ATC C01DA55) could be identified.</p><h4>References</h4><ol><li>J D Gilbert, R I Aylott, H H SÃ¶gtrop, G H Draffan,The pharmacokinetics of meprobamate following its oral and rectal administration as a series of combinations with diphenhydramine, acetylsalicylic acid, codeine and pentaerythritol tetranitrate.,Arzneimittel-Forschung,1984<a href='https://pubmed.ncbi.nlm.nih.gov/6549136/'>https://pubmed.ncbi.nlm.nih.gov/6549136/</a></li><li>R Kirsten, K Nelson, D Kirsten, B Heintz,Clinical pharmacokinetics of vasodilators. Part II.,Clinical pharmacokinetics,1998<a href='https://pubmed.ncbi.nlm.nih.gov/9673832/'>https://pubmed.ncbi.nlm.nih.gov/9673832/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01DA55;
